The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.
Minireview: The Glucagon-Like Peptides
Abstract
The glucagon-like peptides GLP-1 and GLP-2 are produced in enteroendocrine L cells of the small and large intestine and secreted in a nutrient-dependent manner. GLP-1 regulates nutrient assimilation via inhibition of gastric emptying and food intake. GLP-1 controls blood glucose following nutrient absorption via stimulation of glucose-dependent insulin secretion, insulin biosynthesis, islet proliferation, and neogenesis and inhibition of glucagon secretion. Experiments using GLP-1 antagonists and GLP-1 receptor-/- mice indicate that the glucoregulatory actions of GLP-1 are essential for glucose homeostasis. In the central nervous system, GLP-1 regulates hypothalamic-pituitary function and GLP-1-activated circuits mediate the CNS response to aversive stimulation. GLP-2 maintains the integrity of the intestinal mucosal epithelium via effects on gastric motility and nutrient absorption, crypt cell proliferation and apoptosis, and intestinal permeability. Both GLP-1 and GLP-2 are rapidly inactivated in the circulation as a consequence of amino-terminal cleavage by the enzyme dipeptidyl peptidase IV (DP IV). The actions of these peptides on nutrient absorption and energy homeostasis and the efficacy of GLP-1 and GLP-2 in animal models of diabetes and intestinal diseases, respectively, suggest that analogs of these peptides may be clinically useful for the treatment of human disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A role for glucagon-like peptide-1 in the central regulation of feeding
Turton, M. D., O'Shea, D., Gunn, I., Beak, S. A., Edwards, C. M. B., Meeran, K., Choi, S. J., Taylor, G. M., Heath, M. M., Lambert, P. D., et al. (1996) · Nature · doi:10.1038/379069a0 · Cited by 1,950
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Drucker, D. J., Philippe, J., Mojsov, S., Chick, W. L., & Habener, J. F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.10.3434 · Cited by 903 · cited 1×
“GLP-1 increases levels of b cell cAMP and insulin gene transcription and stimulates glucose-dependent insulin release (45); however, unlike other depolarizing agents such as the sulfonylureas, b cell GLP-1R signaling is glucose dependent (46).”
Self-citationInduction of intestinal epithelial proliferation by glucagon-like peptide 2.
Drucker, D. J., Erlich, P., Asa, S. L., & Brubaker, P. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7911 · Cited by 880
Self-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793 · cited 2×
“several months of high fat feeding (30, 31).”
Self-citationDeacon, C. F., Johnsen, A. H., & Holst, J. J. (1995) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.80.3.7883856 · Cited by 792
Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618
Drucker, D. J. (1998) · Diabetes · doi:10.2337/diab.47.2.159 · Cited by 601
Self-citationHansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Holz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594
Stoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Self-citationEnhanced insulin secretion and improved glucose tolerance in mice lacking CD26
Marguet, D., Baggio, L., Kobayashi, T., Bernard, A.-M., Pierres, M., Nielsen, P. F., Ribel, U., Watanabe, T., Drucker, D. J., & Wagtmann, N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.120069197 · Cited by 538
Self-citationGutzwiller, J.-P., Drewe, J., Göke, B., Schmidt, H., Rohrer, B., Lareida, J., & Beglinger, C. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.276.5.r1541 · Cited by 521
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes.
Holst, J. J., & Deacon, C. F. (1998) · Diabetes · doi:10.2337/diabetes.47.11.1663 · Cited by 487
Role of the Vagus Nerve in Mediating Proximal Nutrient-Induced Glucagon-Like Peptide-1 Secretion
Rocca, A. S., & Brubaker, P. L. (1999) · Endocrinology · doi:10.1210/en.140.4.1687 · Cited by 464
CD26, let it cut or cut it down
De Meester, I., Korom, S., Van Damme, J., & Scharpé, S. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01486-3 · Cited by 451
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 1×
“Exogenous GLP-1 stimulates islet cell proliferation in Umea 1/? mice (56) and increases islet cell proliferation in INS-1 cells via a PI3-kinase-dependent pathway (49).”
Endocrine tumour in kidney affecting small bowel structure, motility, and absorptive function
Gleeson, M. H., Bloom, S. R., Polak, J. M., Henry, K., & Dowling, R. H. (1971) · Gut · doi:10.1136/gut.12.10.773 · Cited by 381
Campos, R. V. (1994) · Endocrinology · doi:10.1210/en.134.5.2156 · Cited by 353
Edwards, C. M., Todd, J. F., Mahmoudi, M., Wang, Z., Wang, R. M., Ghatei, M. A., & Bloom, S. R. (1999) · Diabetes · doi:10.2337/diabetes.48.1.86 · Cited by 344
Enteroendocrine localization of GLP-2 receptor expression in humans and rodents
Yusta, B., Huang, L., Munroe, D., Wolff, G., Fantaske, R., Sharma, S., Demchyshyn, L., Asa, S. L., & Drucker, D. J. (2000) · Gastroenterology · doi:10.1053/gast.2000.16489 · Cited by 339
Self-citationToft-Nielsen, M. B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 338
Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2
Munroe, D. G., Gupta, A. K., Kooshesh, F., Vyas, T. B., Rizkalla, G., Wang, H., Demchyshyn, L., Yang, Z.-J., Kamboj, R. K., Chen, H., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1569 · Cited by 328
Self-citationIntestinal growth-promoting properties of glucagon-like peptide-2 in mice
Tsai, C. H., Hill, M., Asa, S. L., Brubaker, P. L., & Drucker, D. J. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.1.e77 · Cited by 319
Self-citationZhou, J., Wang, X., Pineyro, M. A., & Egan, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319
Larsen, P. J. (1997) · Endocrinology · doi:10.1210/en.138.10.4445 · Cited by 316
Exendin-4 Decelerates Food Intake, Weight Gain, and Fat Deposition in Zucker Rats
Szayna, M. (2000) · Endocrinology · doi:10.1210/en.141.6.1936 · Cited by 303
Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM
Nauck, M. A., Wollschläger, D., Werner, J., Holst, J. J., Ørskov, C., Creutzfeldt, W., & Willms, B. (1996) · Diabetologia · doi:10.1007/s001250050613 · Cited by 285
Benjamin, M. A., McKay, D. M., Yang, P.-C., Cameron, H., & Perdue, M. H. (2000) · Gut · doi:10.1136/gut.47.1.112 · Cited by 277
Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
Drucker, D. J., Shi, Q., Crivici, A., Sumner-Smith, M., Tavares, W., Hill, M., DeForest, L., Cooper, S., & Brubaker, P. L. (1997) · Nature Biotechnology · doi:10.1038/nbt0797-673 · Cited by 276
Self-citationRoberge, J. N. (1993) · Endocrinology · doi:10.1210/en.133.1.233 · Cited by 276
Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Interoceptive stress activates glucagon-like peptide-1 neurons that project to the hypothalamus
Rinaman, L. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.2.r582 · Cited by 244
Role of prohormone convertases in the tissue-specific processing of proglucagon
Dhanvantari, S. (1996) · Molecular Endocrinology · doi:10.1210/me.10.4.342 · Cited by 242
GLP-2 augments the adaptive response to massive intestinal resection in rat
Scott, R. B., Kirk, D., MacNaughton, W. K., & Meddings, J. B. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.5.g911 · Cited by 237
Hupe-Sodmann, K., McGregor, G. P., Bridenbaugh, R., Göke, R., Göke, B., Thole, H., Zimmermann, B., & Voigt, K. (1995) · Regulatory Peptides · doi:10.1016/0167-0115(95)00063-h · Cited by 224
Xiao, Q., Boushey, R. P., Drucker, D. J., & Brubaker, P. L. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70555-x · Cited by 210
Self-citationJeppesen, P. B., Hartmann, B., Thulesen, J., Hansen, B. S., Holst, J. J., Poulsen, S. S., & Mortensen, P. B. (2000) · Gut · doi:10.1136/gut.47.3.370 · Cited by 210
Glucagon-Like Peptide-2 Inhibits Centrally Induced Antral Motility in Pigs
M. WØJDEMANN, A. W. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850171486 · Cited by 210
Balkan, B., Kwasnik, L., Miserendino, R., Holst, J. J., & Li, X. (1999) · Diabetologia · doi:10.1007/s001250051445 · Cited by 209
In Vivo and in Vitro Degradation of Glucagon-Like Peptide-2 in Humans1
Hartmann, B., Harr, M. B., Jeppesen, P. B., Wojdemann, M., Deacon, C. F., Mortensen, P. B., & Holst, J. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.8.6717 · Cited by 191
Glucagon-like peptide-1 is a physiological incretin in rat.
Wang, Z., Wang, R. M., Owji, A. A., Smith, D. M., Ghatei, M. A., & Bloom, S. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117671 · Cited by 190
Greig, N. H., Holloway, H. W., De Ore, K. A., Jani, D., Wang, Y., Zhou, J., Garant, M. J., & Egan, J. M. (1999) · Diabetologia · doi:10.1007/s001250051111 · Cited by 189
Jeppesen, P. B., Hartmann, B., Hansen, B. S., Thulesen, J., Holst, J. J., & Mortensen, P. B. (1999) · Gut · doi:10.1136/gut.45.4.559 · Cited by 183
Central infusions of leptin and GLP-1-(7-36) amide differentially stimulate c-FLI in the rat brain
Van Dijk, G., Thiele, T. E., Donahey, J. C., Campfield, L. A., Smith, F. J., Burn, P., Bernstein, I. L., Woods, S. C., & Seeley, R. J. (1996) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1996.271.4.r1096 · Cited by 179
Boushey, R. P., Yusta, B., & Drucker, D. J. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e937 · Cited by 179
Self-citationHuman [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis
Drucker, D. J., Yusta, B., Boushey, R. P., DeForest, L., & Brubaker, P. L. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.276.1.g79 · Cited by 176
Self-citationGlucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats.
Wang, Y., Perfetti, R., Greig, N. H., Holloway, H. W., DeOre, K. A., Montrose-Rafizadeh, C., Elahi, D., & Egan, J. M. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119482 · Cited by 172
Seeley, R. J., Blake, K., Rushing, P. A., Benoit, S., Eng, J., Woods, S. C., & D'Alessio, D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01616.2000 · Cited by 169
Inhibition of Sham Feeding-Stimulated Human Gastric Acid Secretion by Glucagon-Like Peptide-2
Wøjdemann, M., Wettergren, A., Hartmann, B., Hilsted, L., & Holst, J. J. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5840 · Cited by 167
Chen, Y. E., & Drucker, D. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4108 · Cited by 166
Self-citationInitiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umea +/?)
Edvell, A., & Lindström, P. (1999) · Endocrinology · doi:10.1210/endo.140.2.6514 · Cited by 157
Hansen, L., Hartmann, B., Bisgaard, T., Mineo, H., Jørgensen, P. N., & Holst, J. J. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.6.e1010 · Cited by 147
Skoglund, G., Hussain, M. A., & Holz, G. G. (2000) · Diabetes · doi:10.2337/diabetes.49.7.1156 · Cited by 144
Barragán, J. M., Eng, J., Rodríguez, R., & Blázquez, E. (1999) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1999.277.5.e784 · Cited by 142 · cited 1×
“These effects can be blocked by iv or ICV administration of the antagonist exendin (9–39) and bilateral vagotomy blocked the cardiovascular effects of ICV, but not peripherally administered GLP-1 (65).”
Roberge, J. N., Gronau, K. A., & Brubaker, P. L. (1996) · Endocrinology · doi:10.1210/endo.137.6.8641190 · Cited by 142
Circulating and Tissue Forms of the Intestinal Growth Factor, Glucagon-Like Peptide-2
Brubaker, P. L., Crivici, A., Izzo, A. A., Ehrlich, P. F., Tsai, C.-H., & Drucker, D. J. (1997) · Endocrinology · doi:10.1210/endo.138.11.5482 · Cited by 135
Self-citationBeak, S. A., Heath, M. M., Small, C. J., Morgan, D. G., Ghatei, M. A., Taylor, A. D., Buckingham, J. C., Bloom, S. R., & Smith, D. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci610 · Cited by 133
Donahey, J. C. K., van Dijk, G., Woods, S. C., & Seeley, R. J. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01057-3 · Cited by 133
MacLusky, N. J., Cook, S., Scrocchi, L., Shin, J., Kim, J., Vaccarino, F., Asa, S. L., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.2.7326 · Cited by 133
Self-citationPrevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2
Chance, W. T., Foley‐Nelson, T., Thomas, I., & Balasubramaniam, A. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.2.g559 · Cited by 133
Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs.
Sandhu, H., Wiesenthal, S. R., MacDonald, P. E., McCall, R. H., Tchipashvili, V., Rashid, S., Satkunarajah, M., Irwin, D. M., Shi, Z. Q., BRUBAKER, P. L., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1045 · Cited by 132
Casas, J. M. B., Rodríguez, R. E., Eng, J., & Blázquez, E. (1996) · Regulatory Peptides · doi:10.1016/s0167-0115(96)00113-9 · Cited by 125
Drucker, D. J., DeForest, L., & Brubaker, P. L. (1997) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1997.273.6.g1252 · Cited by 123
Self-citationA functional role for central glucagon-like peptide-1 receptors in lithium chloride-induced anorexia
Rinaman, L. (1999) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.1999.277.5.r1537 · Cited by 121
D’Alessio, D. A., Vogel, R., Prigeon, R. L., Laschansky, E. C., Koerker, D. J., Eng, J., & Ensinck, J. W. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118380 · Cited by 119
Vella, A. V., Shah, P., Basu, R., Basu, A., Holst, J. J., & Rizza, R. A. (2000) · Diabetes · doi:10.2337/diabetes.49.4.611 · Cited by 119
Tavares, W., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.2000.278.1.e134 · Cited by 119
Self-citationYusta, B., Somwar, R., Wang, F., Munroe, D. G., Grinstein, S., Klip, A., & Drucker, D. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30459 · Cited by 116
Self-citationYusta, B., Boushey, R. P., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005510200 · Cited by 114
Self-citationNauck, M. A., Sauerwald, A., Ritzel, R. A., Holst, J. J., & Schmiegel, W. (1998) · Diabetes Care · doi:10.2337/diacare.21.11.1925 · Cited by 113
Circulating levels of glucagon-like peptide-2 in human subjects with inflammatory bowel disease
Xiao, Q., Boushey, R. P., Cino, M., Drucker, D. J., & Brubaker, P. L. (2000) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.2000.278.4.r1057 · Cited by 111
Self-citationIrwin, D. M., & Wong, J. (1995) · Molecular Endocrinology · doi:10.1210/mend.9.3.7776976 · Cited by 101
Scrocchi, L. A., & Drucker, D. J. (1998) · Endocrinology · doi:10.1210/endo.139.7.6092 · Cited by 95
Self-citationBaggio, L. L., Kieffer, T. J., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.10.7720 · Cited by 93
Self-citationGlucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitus
Todd, J. F., Wilding, J. P. H., Edwards, C. M. B., KHAN, F. A., Ghatei, M. A., & Bloom, S. R. (1997) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1997.1490691.x · Cited by 93
Bode, H., Moormann, B., Dabew, R., & Göke, B. (1999) · Endocrinology · doi:10.1210/endo.140.9.6947 · Cited by 92
Thiele, T. E., Seeley, R. J., D’Alessio, D. D., Eng, J., Bernstein, I. L., Woods, S. C., & van Dijk, G. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00584-8 · Cited by 88
Glucagonoma syndrome demonstrating giant duodenal villi.
Stevens, F. M., Flanagan, R., O’Gorman, D. J., & Buchanan, K. D. (1984) · Gut · doi:10.1136/gut.25.7.784 · Cited by 87
Ontogeny of the Glucagon-Like Peptide-2 Receptor Axis in the Developing Rat Intestine
Lovshin, J. A., Yusta, B., Iliopoulos, I. D., Migirdicyan, A., Dableh, L. J., Brubaker, P. L., & Drucker, D. J. (2000) · Endocrinology · doi:10.1210/endo.141.11.7773 · Cited by 87
Self-citationGLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions
Gutniak, M., Larsson, H., Sanders, S. W., Juneskans, O. T., Holst, J. J., & Åhrén, B. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1874 · Cited by 84
Gutniak, M., Juntti‐Berggren, L., Hellström, P. M., Guenifi, A., Holst, J. J., & Efendić, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.8.857 · Cited by 76
Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats
Fischer, K. D., Dhanvantari, S., Drucker, D. J., & Brubaker, P. L. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.4.e815 · Cited by 76
Self-citationBeak, S. A., Small, C. J., Иловайская, И. А., Hurley, J. D., Ghatei, M. A., Bloom, S. R., & Smith, D. M. (1996) · Endocrinology · doi:10.1210/endo.137.10.8828468 · Cited by 71
Flamez, D., Gilon, P., Moens, K., Breusegem, A. V., Delmeire, D., Scrocchi, L. A., Henquin, J., Drucker, D. J., & Schuit, F. C. (1999) · Diabetes · doi:10.2337/diabetes.48.10.1979 · Cited by 65
Self-citationDrucker, D. J. (1999) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(98)00136-2 · Cited by 65
Self-citationScrocchi, L. A., Hill, M. E., Saleh, J., Perkins, B. A., & Drucker, D. J. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1552 · Cited by 60
Self-citationHoyt, E. C., Lund, P. K., Winesett, D. E., Fuller, C. R., Ghatei, M. A., Bloom, S. R., & Ulshen, M. H. (1996) · Diabetes · doi:10.2337/diab.45.4.434 · Cited by 59
Glucagonlike peptide-2 analogue enhances intestinal mucosal mass after ischemia and reperfusion
Prasad, R., Alavi, K., & Schwartz, M. Z. (2000) · Journal of Pediatric Surgery · doi:10.1016/s0022-3468(00)90040-x · Cited by 59
Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats
Gülpınar, M. A., Bozkurt, A., Coşkun, T., Ulusoy, N. B., & Yeğen, B. Ç. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.278.6.g924 · Cited by 53
Joseph, J. W., Kalitsky, J., St-Pierre, S. A., & Brubaker, P. L. (2000) · Diabetologia · doi:10.1007/s001250051529 · Cited by 47
Baggio, L. L., Adatia, F. A., Bock, T. G., Brubaker, P. L., & Drucker, D. J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005119200 · Cited by 46
Self-citationThe influence of the colon on postprandial glucagon-like peptide 1 (7-36) amide concentration in man
Robertson, M. D., Livesey, G., Morgan, L., Hampton, S., & Mathers, J. C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1610025 · Cited by 28
Cited by
Pathogenesis of type 2 diabetes mellitus
DeFronzo, R. A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.013 · Cited by 1,342
Acetate mediates a microbiome–brain–β-cell axis to promote metabolic syndrome
Perry, R. J., Peng, L., Barry, N. A., Cline, G. W., Zhang, D., Cardone, R. L., Petersen, K. F., Kibbey, R. G., Goodman, A. L., & Shulman, G. I. (2016) · Nature · doi:10.1038/nature18309 · Cited by 1,299
New drug targets for type 2 diabetes and the metabolic syndrome
Moller, D. E. (2001) · Nature · doi:10.1038/414821a · Cited by 1,008
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851
Self-citationRubino, F., Gagner, M., Gentileschi, P., Kini, S., Fukuyama, S., Feng, J., & Diamond, E. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000133117.12646.48 · Cited by 639
Metadata
- Authors
- Drucker, D. J.
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2001-02-01
- Volume
- 142
- Issue
- 2
- Pages
- 521-527
- ISSN
- 0013-7227 (ISSN-L)
- OpenAlex
- W2140137473
- Cited by
- 421
- References
- 96
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.